scispace - formally typeset
D

David Cameron

Researcher at University of Oslo

Publications -  1765
Citations -  141776

David Cameron is an academic researcher from University of Oslo. The author has contributed to research in topics: Large Hadron Collider & Breast cancer. The author has an hindex of 154, co-authored 1586 publications receiving 126067 citations. Previous affiliations of David Cameron include Universidade Nova de Lisboa & Cameron International.

Papers
More filters
Journal ArticleDOI

Measurement of the pseudorapidity and transverse momentum dependence of the elliptic flow of charged particles in lead-lead collisions at sNN=2.76 TeV with the ATLAS detector

Georges Aad, +3005 more
- 01 Feb 2012 - 
TL;DR: In this article, the authors describe the measurement of elliptic flow of charged particles in lead-lead collisions at root s(NN) = 2.76 TeV using the ATLAS detector at the Large Hadron Collider (LHC).
Journal ArticleDOI

Search for additional heavy neutral Higgs and gauge bosons in the ditau final state produced in 36 fb−1 of pp collisions at √s=13 TeV with the ATLAS detector

Morad Aaboud, +50 more
- 12 Jan 2018 - 
TL;DR: In this article, a search for heavy neutral Higgs bosons and Z' bosons was performed using a data sample corresponding to an integrated luminosity of 36.1 fb(-1) from proton-proton collisions at root s = 13 TeV reco...
Journal ArticleDOI

Measurements of Higgs boson properties in the diphoton decay channel with 36 fb−1 of pp collision data at s√=13 TeV with the ATLAS detector

Morad Aaboud, +2929 more
- 18 Sep 2018 - 
TL;DR: In this paper, the properties of the Higgs boson were measured in the two-photon final state using 36.1 fb-1 of proton? proton collision data recorded at ffiffi √s = 13 TeV by the ATLAS experiment at the Large Hadron Collider.
Journal ArticleDOI

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

Robert E. Coleman, +15 more
- 01 Aug 2014 - 
TL;DR: No overall benefit is suggested from the addition of zoledronic acid to standard adjuvant treatments for early breast cancer, however, zoledronics acid does reduce the development of bone metastases and, for women with established menopause, improved disease outcomes.
Journal ArticleDOI

Measurement of the inclusive W± and Z/γ∗ cross sections in the e and μ decay channels in pp collisions at √s=7TeV with the ATLAS detector

Georges Aad, +3037 more
- 24 Apr 2012 - 
TL;DR: In this paper, the production cross sections of the inclusive Drell-Yan processes W-+/- -> l nu and Z/gamma* -> ll (l = e, mu) are measured in proton-proton collisions at root s = 7 TeV with the ATLAS detector.